Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Carcinoma Clear all
Completed No phase listed Observational Accepts healthy volunteers

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer

NCT01662609
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Endoscopic Ultrasound (EUS)
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
30 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 14, 2026, 8:58 PM EDT
Recruiting Phase 1 Interventional

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

NCT03484299
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Irreversible Electroporation (IRE), Gemcitabine, FOLFIRINOX
Procedure · Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 14, 2026, 8:58 PM EDT
Terminated No phase listed Observational

Identify microRNAs in Cachexia in Pancreatic Carcinoma

NCT05275075
View directory record Official record
Conditions
Resectable Pancreatic Adenocarcinoma
Interventions
Pancreatic cancer microRNA and messenger RNA expression.
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 1 Interventional Results available

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
Combination Product
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

NCT02583477
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
MEDI4736 in combination with nab-paclitaxel and gemcitabine, MEDI4736 in combination with AZD5069
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 14, 2026, 8:58 PM EDT
Terminated Not applicable Interventional

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

NCT00159471
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
capecitabine, gemcitabine, docetaxel
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

NCT00002475
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions
allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 14, 2026, 8:58 PM EDT
Active, not recruiting Phase 1 Interventional

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Dasatinib, Erlotinib Hydrochloride, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 14, 2026, 8:58 PM EDT
Terminated Phase 3 Interventional

S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen

NCT00602745
View directory record Official record
Conditions
Pancreatic Neoplasm, Neoplasm Metastasis
Interventions
S-1, 5-Fluorouracil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

Tarceva and Capecitabine for Pancreatic Cancer

NCT00125021
View directory record Official record
Conditions
Pancreatic Cancer, Neoplasm Metastasis
Interventions
Capecitabine, OSI-774
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

NCT03801915
View directory record Official record
Conditions
Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma, Liver Metastasis
Interventions
MVT-5873, pancreatectomy or hepatectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Not applicable Interventional

Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis

NCT03152487
View directory record Official record
Conditions
Pancreatic Carcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer, Pancreatic Cancer, Adult
Interventions
Celiac Plexus Neurolysis, Radiofrequency Ablation
Other
Lead sponsor
AdventHealth
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 14, 2026, 8:58 PM EDT
Completed No phase listed Observational

Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors

NCT01603004
View directory record Official record
Conditions
Pancreatic Neuroendocrine Cancer
Interventions
MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 14, 2026, 8:58 PM EDT
Active, not recruiting Early Phase 1 Interventional

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

NCT04665947
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions
[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT02243358
View directory record Official record
Conditions
Pancreas Neoplasm Malignant Resectable
Interventions
Folfox6, Gemcitabine, Radiation Therapy, Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
Drug · Radiation · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 14, 2026, 8:58 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 1 Interventional

Gem-TABS in Unresectable Pancreatic Carcinoma

NCT01198821
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Sodium bicarbonate (g/kg/day), Gemcitabine (mg/m²)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 14, 2026, 8:58 PM EDT
Active, not recruiting Phase 2 Interventional

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

NCT02955940
View directory record Official record
Conditions
Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
Interventions
Ruxolitinib, Capecitabine, Regorafenib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Louisville, Kentucky • Clifton Park, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 14, 2026, 8:58 PM EDT
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03797443
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ascorbic Acid, nab paclitaxel, Cisplatin, Gemcitabine
Drug
Lead sponsor
Piedmont Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Fayetteville, Georgia • Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Not applicable Interventional Results available

Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle

NCT01769248
View directory record Official record
Conditions
Pancreatic Cancer, Lymphadenopathy, Gastrointestinal Stromal Tumor
Interventions
Fine needle aspiration, Fine needle biopsy
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 14, 2026, 8:58 PM EDT
Completed No phase listed Observational

Immunologic Signatures Following Surgery for Pancreatic Cancer

NCT03001518
View directory record Official record
Conditions
Pancreatic Cancer, Surgery
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 14, 2026, 8:58 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

NCT07698613
View directory record Official record
Conditions
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable
Interventions
ASP-1929 photoimmunotherapy
Combination Product
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 14, 2026, 8:58 PM EDT
Completed Phase 1 Interventional

Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

NCT00183846
View directory record Official record
Conditions
Pancreatic Cancer, Gastric Cancer, Duodenum Cancer, Bile Duct Cancer
Interventions
irinotecan, radiation therapy
Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 14, 2026, 8:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633
View directory record Official record
Conditions
Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
[18F]FPyQCP
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 8:58 PM EDT